Crossmark

Risk of Incident Immune-Mediated Inflammatory Diseases with Second Tumor Necrosis Factor Inhibitor Versus Alternative Biologic Therapy in Patients with Inflammatory Bowel Disease and First TNFi Exposure: A Real-World Cohort Study

Crossref DOI link: https://doi.org/10.1007/s10620-025-09598-4

Published Online: 2025-12-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Desai, Aakash

Kochhar, Gursimran S.

Khataniar, Himsikhar

Hashash, Jana G.

Farraye, Francis A.
License Information

Text and Data Mining valid from 2025-12-09

Version of Record valid from 2025-12-09
More Information

Article History

Received: 27 August 2025

Accepted: 1 December 2025

First Online: 9 December 2025

Declarations

:

: AD and HK: None exist GSK: Speaker: Eli Lilly Pharma. Advisory Board: GIE Medical, Eli Lilly Pharma, Consultant: Pentax endoscopy, Olympus endoscopy, Boston Scientific endoscopy, Takeda Pharmaceuticals. Stock Options: Digbi Health JGH: Advisory Board BMS. FAF: Consulting Fee: Astellas, Avalo Therapeutics, Bausch, Biocon, Braintree Labs, GI Reviewers, GSK, IBD Educational Group, Iterative Health, Janssen, Metaphore Biotechnologies, Pharmacosmos, Pfizer, Sandoz Immunology. DSMB: Eli Lilly, MoonLake.

Document is current

Any future updates will be listed below